Company Interview / ResMed sleeping well at night

ResMed's (ASX: RMD) CEO Mick Farrell shares strong quarterly results, with shares jumping 7.5% locally. Driven by double-digit growth across regions and products, ResMed (ASX: RMD) reports an 11% revenue increase to $1.22 billion, beating expectations.

Mick notes that GLP-1 drugs, once seen as a potential threat, are instead bringing more patients to ResMed's (ASX: RMD) sleep health solutions. With millions at risk, a combination of therapies enhances treatment, welcoming new technologies like Samsung and Apple for detection.

Mick unveils ResMed's 2030 strategy targeting 500 million lives. Emphasising its competitive edge, the company leverages its vast digital health ecosystem. By investing 7% of revenue into R&D, ResMed aims to lead and innovate in sleep and respiratory care.